HCC podcast series part 1: The use of IO in unresectable HCC

November 21, 2024 00:23:21
HCC podcast series part 1: The use of IO in unresectable HCC
COR2ED - Oncology Medical Conversation
HCC podcast series part 1: The use of IO in unresectable HCC

Nov 21 2024 | 00:23:21

/

Show Notes

In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include: 

 

 

Key clinical takeaways:

 

 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

 

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme. 

 

This podcast is developed by cor2ed.com 

Published on November 2024 

 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Other Episodes

Episode

December 06, 2023 00:22:49
Episode Cover

Prostate cancer: PARP inhibitors. Part 3 - Efficacy and safety of combination therapy

Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the...

Listen

Episode

April 25, 2024 00:32:21
Episode Cover

Cáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores

¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones...

Listen

Episode

May 28, 2024 00:21:47
Episode Cover

Regional differences in NET: Epidemiology, diagnosis, and referral strategies

In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient...

Listen